MeiraGTx Q2 revenue jumps on Reogen license revenue

MeiraGTx Holdings

13/08/2026 13:22

Overview
UK-U.S. genetic medicines firm's Q2 revenue surged
Company posted net income after a loss in the prior-year quarter
MeiraGTx completed bota-vec acquisition from J&J and secured up to $400 mln investment from Oberland Capital

Outlook
Company expects global regulatory filings for bota-vec in 2026 and potential launch in 2027
MeiraGTx plans potential BLA filing for AAV2-hAQP1 in mid-2027, targeting U.S. launch in 2028
Company expects to initiate Phase 3 study of AAV-GAD for Parkinson’s disease in coming months

Result Drivers
LICENSE REVENUE - Co recognized $204.6 mln in license revenue from granting rights to Reogen for AAV-GAD and AAV-BDNF programs and delivery device
SERVICE REVENUE - Service revenue rose due to contract manufacturing for Lilly and transition services for Reogen, including release of deferred revenue from terminated J&J agreements
R&D EXPENSES - Research and development expenses increased mainly due to reacquisition of bota-vec from J&J and higher clinical trial spend for AAV2-hAQP1

Company press release: ID:nGNXqtJtg

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
 
$321.43 mln
 
Q2 Net Income
 
$160.67 mln
 
Q2 Income from Operations
 
$244.43 mln
 
Q2 Operating Expenses
 
$77.009 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for MeiraGTx Holdings PLC is $26.00, about 100.6% above its August 12 closing price of $12.96

Reuters Recommended Reads
Aug 11 - Taysha Gene Therapies Q2 net loss widens on higher R&D costs
Aug 10 - Rocket Pharmaceuticals posts Q2 profit helped by PRV sale
Aug 13 - Abeona Therapeutics Q2 net loss widens, misses analyst expectations

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)